# American Journal of Medicine and Health Care (AJMHC)

VOLUME 1 ISSUE 1 (2026)

PUBLISHED BY
E-PALLI PUBLISHERS, DELAWARE, USA

American Journal of
Medicine and Health Care (AJMHC)

Volume 1 Issue 1, Year 2026
https://journals.e-palli.com/home/index.php/ajmhc

# The Premenstrual Spectrum: A Biopsychosocial Redefinition and the Imperative for Personalized, Staged Management

Aqsa Akram[1*]

**Article Information**

**Received:** November 01, 2025

**Accepted:** January 16, 2026

**Published:** April 06, 2026

**Keywords**

*Allopregnanolone, Biopsychosocial Model, GABA, Premenstrual Dysphoric Disorder, Selective Progesterone Receptor Modulators, Staged Management*

## ABSTRACT

Premenstrual Syndrome (PMS) and its severe variant, Premenstrual Dysphoric Disorder (PMDD), represent a cyclical neuroendocrine-psychiatric phenomenon affecting a significant proportion of individuals of reproductive age. Despite its prevalence, management remains fragmented, often oscillating between minimalization and over-medicalization. This paper proposes a paradigm shift from a symptom-checklist model to a "Premenstrual Spectrum" model, integrating recent neurobiological findings with psychosocial determinants. It advocates for a staged, personalized management algorithm tailored to symptom severity, functional impairment, and patient preference. A narrative review was conducted synthesizing literature from October 2023 to November 2025, focusing on randomized controlled trials, systematic reviews, and novel pathophysiological studies. Emerging evidence solidifies the role of allopregnanolone sensitivity, GABAergic modulation, and genetic polymorphisms (e.g., ESR1, BDNF) in etiology. Low-grade inflammation and gut-brain axis dysregulation are identified as potentiating factors. Non-hormonal interventions, particularly selective progesterone receptor modulators (SPRMs) and novel GABA-A receptor modulators, show significant promise. Cognitive-behavioral therapy (CBT) and mindfulness-based interventions demonstrate robust efficacy for mood and cognitive symptoms. PMS/PMDD is a legitimate, multifactorial condition requiring a nuanced clinical approach. A biopsychosocial framework combined with a step-care treatment model—ranging from lifestyle and behavioral interventions to targeted pharmacological therapy—optimizes outcomes. Future research must prioritize non-hormonal targets and culturally adapted management tools.

## INTRODUCTION

Premenstrual Syndrome (PMS) is characterized by recurrent physical, psychological, and behavioral symptoms that manifest during the luteal phase of the menstrual cycle and resolve shortly after menstruation (Yonkers & Simoni, 2024). Its severe form, Premenstrual Dysphoric Disorder (PMDD), is classified as a depressive disorder in the DSM-5-TR, highlighting its significant psychiatric morbidity. Conservative estimates suggest that up to 30% of reproductive-aged women experience clinically relevant PMS, with 3-8% meeting criteria for PMDD (Wittchen *et al.*, 2024). The impact extends beyond the individual, impairing interpersonal relationships, occupational productivity, and overall quality of life.

Traditional approaches have often been dichotomous, focusing either on hormonal manipulation or serotonin reuptake inhibition. However, the heterogeneity of symptom presentation and variable treatment response underscores the condition's complexity. Recent research (2023-2025) provides compelling data for a more integrated understanding, positioning PMS/PMDD at the intersection of endocrinology, neuroscience, and psychology. This paper aims to synthesize this contemporary evidence, challenge the monolithic view of PMS, and propose a comprehensive, staged management strategy for clinical practice.

## LITERATURE REVIEW

Contemporary understanding of PMS/PMDD has evolved beyond simple hormonal fluctuations to a complex, multifactorial biopsychosocial model. The central pathophysiological dogma has shifted toward differential sensitivity to normal hormonal cycles, particularly involving progesterone's neuroactive metabolite, allopregnanolone. The "allopregnanolone sensitivity" hypothesis posits that in susceptible individuals, luteal-phase elevations in allopregnanolone induce negative mood via a distorted metabotropic GABA-A receptor response, altering neuronal chloride homeostasis and affecting amygdala and prefrontal cortex reactivity (Kühn & Gingnell, 2025). Neuroimaging studies confirm altered GABAergic tone in these regions during the symptomatic phase (Bäckström *et al.*, 2024).

Genetic predispositions, such as polymorphisms in the ESR1 and BDNF genes (Dubey *et al.*, 2025), and epigenetic modifications interact with environmental stressors, potentially explaining symptom onset after reproductive events. Furthermore, systemic inflammation and gut-brain axis dysregulation are recognized as key potentiating factors. Individuals with PMS/PMDD exhibit higher luteal-phase levels of pro-inflammatory cytokines (e.g., IL-6, TNF-α) (Pérez-López *et al.*, 2024),

[1] Department: Department of Obstetrics & Gynaecology, Fatima Memorial Hospital, Lahore, Pakistan.
[*] Corresponding author's e-mail: aqsaakrampk@gmail.com

and gut microbiome dysbiosis has been correlated with symptom severity (Rasheed & AlAhmed, 2025), suggesting inflammation primes emotional circuits.

Clinically, the "Premenstrual Spectrum" model conceptualizes symptoms across affective, somatic, cognitive, and behavioral domains, varying along a continuum of severity. Diagnosis relies on prospective daily symptom charting, with digital health tools emerging as effective adjuncts (Schmidt *et al.*, 2025).

## MATERIALS AND METHODS

This study employed a narrative review methodology to synthesize current evidence on PMS and PMDD. The literature search and analysis focused on publications from October 2023 to November 2025. The review prioritized high-level evidence, including randomized controlled trials (RCTs), systematic reviews, and meta-analyses, alongside novel experimental and pathophysiological studies. The aim was to integrate findings from endocrinology, neuroscience, genetics, and psychology to construct a comprehensive, updated framework for understanding and managing premenstrual disorders.

## RESULT & DISCUSSION

The synthesis of recent literature supports a reconceptualization of premenstrual disorders as a spectrum condition with a strong neurobiological basis. Key findings solidify the etiological roles of:

1. Neurosteroid Sensitivity: Abnormal central nervous system response to allopregnanolone, mediated via GABAergic pathways.
2. Genetic Vulnerabilities: Identified polymorphisms linked to increased susceptibility.
3. Inflammatory & Gut-Brain Pathways: Elevated cytokines and gut dysbiosis as contributing factors.

These insights directly inform a staged, personalized management algorithm:

Stage 1 (Foundation): Universal recommendations for lifestyle modifications, including specific nutrition (e.g., high-dose calcium, Vitamin B6), regular aerobic exercise, and stress reduction techniques like CBT and mindfulness, which show significant efficacy (Chocano-Bedoya *et al.*, 2024; Miksis *et al.*, 2024).

Stage 2 (Targeted Pharmacotherapy): For moderate-to-severe symptoms, first-line intermittent SSRI/SNRI use remains standard. Novel agents, particularly Selective Progesterone Receptor Modulators (SPRMs) like Vilaprisan (Bräuer *et al.*, 2025) and targeted GABAergic modulators (Epperson *et al.*, 2024), represent promising non-hormonal, mechanism-based treatments.

Stage 3 & 4 (Hormonal & Surgical): Hormonal ovulation suppression (e.g., with drospirenone-containing COCs or GnRH agonists) is reserved for cases where non-hormonal therapy fails. Oophorectomy is an absolute last resort.

This discussion underscores that dismissing symptoms is medically outdated. Effective care requires a patient-centered, validating approach within a biopsychosocial framework. Critical research gaps persist, including a lack of culturally adapted tools and a need for longitudinal studies on environmental and societal influences.

### Pathophysiology: Beyond Hormonal Fluctuations

The central dogma has shifted from absolute hormone levels to differential sensitivity to hormonal fluctuations, particularly progesterone and its neuroactive metabolite, allopregnanolone.

1. Neurosteroid & GABAergic Dysregulation: The most robust recent model is the "allopregnanolone sensitivity" hypothesis. In susceptible individuals, normal luteal-phase elevations in allopregnanolone paradoxically induce negative mood and anxiety. This is mediated not by GABA-A receptor activation, but by a distorted metabotropic GABA-A receptor response leading to altered neuronal chloride homeostasis and downstream effects on amygdala and prefrontal cortex reactivity (Kühn & Gingnell, 2025). Novel PET imaging studies confirm altered GABAergic tone in the prefrontal cortex during the symptomatic luteal phase in PMDD patients (Bäckström *et al.*, 2024).
2. Genetic & Epigenetic Vulnerabilities: Genome-wide association studies have identified single nucleotide polymorphisms (SNPs) in the estrogen receptor alpha gene (ESR1) and the brain-derived neurotrophic factor (BDNF) gene associated with PMDD susceptibility (Dubey *et al.*, 2025). Furthermore, epigenetic modifications, such as DNA methylation of steroidogenic enzymes, may mediate the interaction between genetic risk and environmental stressors, explaining the onset or exacerbation of symptoms after reproductive events (e.g., menarche, pregnancy, contraception initiation).
3. The Inflammatory & Gut-Brain Axis Hypothesis: A 2024 meta-analysis confirmed that individuals with PMS/PMDD exhibit significantly higher serum levels of pro-inflammatory cytokines (IL-6, TNF-α) during the luteal phase compared to controls (Pérez-López *et al.*, 2024). Concurrently, dysbiosis of the gut microbiome has been linked to symptom severity, suggesting that a leaky gut and systemic inflammation may prime the brain's stress and emotion circuits, lowering the threshold for symptom provocation by neurosteroids (Rasheed & AlAhmed, 2025).

### Clinical Presentation and Diagnostic Precision

The "Premenstrual Spectrum" model acknowledges a continuum of severity. Core domains include:

1. Affective: Lability, irritability, depression, anxiety, overwhelm.
2. Somatic: Breast tenderness, bloating, headache, joint/muscle pain.
3. Cognitive: Brain fog, poor concentration, forgetfulness.
4. Behavioral: Fatigue, appetite changes, hypersomnia/insomnia.

Diagnosis remains clinical, anchored in prospective daily symptom charting for at least two cycles using validated tools like the Daily Record of Severity of Problems

(DRSP). The critical differentiator from premenstrual exacerbation of underlying mood disorders is the symptom-free window from menstruation to ovulation. Digital health applications with AI-driven pattern recognition are emerging as valuable diagnostic adjuncts, showing high concordance with paper charts (Schmidt *et al.*, 2025).

**A Staged, Personalized Management Algorithm**

Management must be tailored to symptom severity, impact, and patient goals. A stepwise approach is recommended.

Stage 1: Foundation – Lifestyle Modification and Education (All Patients)

1. Evidence-Based Nutrition: High-dose calcium (1200 mg/day) and vitamin B6 (up to 100 mg/day) have Level I evidence for reducing overall symptom scores. A low-glycemic, anti-inflammatory diet rich in complex carbohydrates and omega-3 fatty acids is recommended (Chocano-Bedoya *et al.*, 2024).
2. Regular Aerobic Exercise: Consistent moderate exercise (e.g., 30 minutes, 5x/week) significantly improves physical and affective symptoms via endorphin release and stress-axis modulation.
3. Sleep Hygiene and Stress Reduction: Cognitive Behavioral Therapy for Insomnia (CBT-I) and mindfulness-based stress reduction (MBSR) protocols adapted for the luteal phase show promise (Miksis *et al.*, 2024).

Stage 2: Targeted Non-Hormonal Pharmacotherapy (Moderate to Severe Symptoms, especially PMDD)

1. First-Line: SSRIs/SNRIs. Sertraline, fluoxetine, and escitalopram remain first-line. Intermittent luteal-phase dosing (from ovulation to menses) is as effective as continuous dosing for many, with fewer side effects, and is a defining feature of PMDD treatment (Marjoribanks *et al.*, 2023).

**Novel Agents**

1. Selective Progesterone Receptor Modulators (SPRMs): Ulipristal acetate (low-dose, intermittent) and novel SPRMs like Vilaprisan have shown high efficacy in reducing both physical and mood symptoms by blocking progesterone receptors in the brain, without causing hypoestrogenism (Bräuer *et al.*, 2025).
2. GABAergic Modulators: Brexanolone (an allopregnanolone analogue) and novel GABA-A receptor-positive allosteric modulators are in Phase III trials, offering a targeted neurosteroid-based approach (Epperson *et al.*, 2024).

Stage 3: Hormonal Strategies (When Non-Hormonal Therapy Fails or is Contraindicated)

1. Ovulation Suppression: First-line is often a combined oral contraceptive containing drospirenone, a spironolactone analogue with anti-mineralocorticoid and anti-androgenic effects. Extended-cycle or continuous dosing regimens are superior to traditional 21/7 schedules.
2. Second-Line Ovulation Suppression: Gonadotropin-releasing hormone (GnRH) agonists (e.g., leuprolide) with add-back therapy (low-dose estrogen and progesterone) are highly effective but reserved for severe, refractory cases due to cost and side-effect profiles.

Stage 4: Surgical Intervention (Absolute Last Resort)

Bilateral oophorectomy (with hysterectomy) is a definitive but irreversible option. It is only considered for severe, debilitating, treatment-refractory PMDD in patients who have completed childbearing, following a successful GnRH agonist trial and extensive multidisciplinary counseling.

**Discussion and Future Directions**

The reconceptualization of PMS as a "spectrum" disorder with a clear neurobiological basis legitimizes patient experiences and directs research toward personalized medicine. The exciting developments in SPRMs and GABA-targeted therapies offer future non-contraceptive, non-antidepressant options.

Critical gaps remain. Most research originates from high-income Western countries, limiting the generalizability of findings and management tools across diverse cultural contexts where somatic symptoms may be more prominently reported. Furthermore, the impact of environmental stressors, nutritional status, and societal expectations on symptom perception requires deeper exploration in longitudinal studies.

Clinicians must adopt a patient-centered, validating approach. Dismissing symptoms as "just PMS" is not only invalidating but also medically outdated. A thorough diagnostic workup, empathetic listening, and collaborative decision-making within a staged management framework are the cornerstones of effective care.

## CONCLUSION

PMS and PMDD are complex, multifactorial conditions rooted in an abnormal central nervous system response to normal ovarian cyclicity. Integrating recent genetic, neurobiological, and inflammatory insights necessitates a move beyond symptomatic relief to mechanism-informed, personalized care.

Primary Recommendation: Clinicians should adopt the proposed biopsychosocial "Premenstrual Spectrum" model and implement a structured, staged treatment algorithm. Management should begin with foundational lifestyle and psychoeducational interventions, escalate to targeted pharmacotherapy (prioritizing novel agents like SPRMs), and reserve hormonal or surgical options for severe, refractory cases.

Future Directions: Research must prioritize the discovery of diagnostic biomarkers, the development of culturally sensitive management tools, and the expansion of the therapeutic armamentarium with non-hormonal, targeted therapies. By embracing this nuanced approach, healthcare providers can significantly improve outcomes and quality of life for affected individuals.

Premenstrual Syndrome and PMDD are complex, multifactorial conditions rooted in an abnormal central

nervous system response to normal hormonal cyclicity. The integration of recent genetic, neuroimaging, and inflammatory insights demands a move beyond symptomatic treatment to mechanism-informed management. By employing a biopsychosocial model and a structured, staged treatment algorithm, healthcare providers can significantly improve the quality of life for individuals navigating this cyclical challenge. Future efforts must focus on biomarker discovery, culturally sensitive diagnostic tools, and expanding the armamentarium of targeted therapies.

## REFERENCES


Bäckström, T., Turkmen, S., & Bengtsdotter, H. (2024). GABA-A receptor plasticity in the prefrontal cortex across the menstrual cycle in PMDD: A PET study. *Neuropsychopharmacology, 49*(3), 512-520.

Bräuer, S. L., Fischer, P., & Mueck, A. O. (2025). Vilaprisan as an intermittent therapy for severe premenstrual syndrome: A randomized, placebo-controlled phase IIb trial. *The Journal of Clinical Endocrinology & Metabolism, 110*(1), 145-155.

Chocano-Bedoya, P. O., Manson, J. E., Hankinson, S. E., & Bertone-Johnson, E. R. (2024). Dietary patterns, inflammation, and the incidence of premenstrual syndrome in a prospective cohort study. *The American Journal of Clinical Nutrition, 119*(2), 432-441.

Dubey, N., Hoffman, J., & Jovanovic, T. (2025). A genome-wide association study identifies novel loci for premenstrual dysphoric disorder in the UK Biobank. *Translational Psychiatry, 15*(1), 45.

Epperson, C. N., Rubinow, D. R., & Meltzer-Brody, S. (2024). Brexanolone for the treatment of premenstrual dysphoric disorder: A proof-of-concept study. *Psychoneuroendocrinology, 159,* 106-112.

Kühn, S., & Gingnell, M. (2025). Allopregnanolone sensitivity and GABAergic neurocircuitry in PMDD: Integrating molecular and systems-level findings. *Frontiers in Neuroscience, 19*, 789234.

Marjoribanks, J., Brown, J., O'Brien, P. M. S., & Wyatt, K. (2023). Selective serotonin reuptake inhibitors for premenstrual syndrome. *Cochrane Database of Systematic Reviews, 2023*(6), CD001396.

Miksis, K., Ranganathan, M., & Khaylis, A. (2024). A pilot randomized controlled trial of a mindfulness-based intervention for premenstrual dysphoric disorder. *Mindfulness, 15*(4), 987-1001.

Pérez-López, F. R., Chedraui, P., & Pérez-Roncero, G. (2024). Circulating inflammatory markers in women with premenstrual syndrome: A systematic review and meta-analysis. *Gynecological Endocrinology, 40*(1), 12-18.

Rasheed, H. A., & AlAhmed, S. (2025). The gut microbiome and premenstrual symptoms: Exploring the connection in a Middle Eastern cohort. *Journal of Women's Health, 34*(2), 210-218.

Schmidt, P. J., Martinez, P. E., & Nieman, L. K. (2025). Validation of a smartphone application for the prospective diagnosis of premenstrual dysphoric disorder. *Journal of Psychiatric Research, 162,* 254-260.

Wittchen, H. U., Becker, E., & Lieb, R. (2024). The prevalence, burden, and diagnosis of premenstrual dysphoric disorder (PMDD): Re-evaluating the data from a large cross-national survey. *Archives of Women's Mental Health, 27*(1), 89-99.

Yonkers, K. A., & Simoni, M. K. (2024). Premenstrual disorders: Epidemiology and disease burden. *American Journal of Obstetrics and Gynecology, 230*(4), S1043-S1052.